Tiessen RG, et al. - Researchers evaluated the safety and tolerability, and the pharmacodynamic (PD) and pharmacokinetic (PK) effects, of multiple doses of volixibat administered orally over a 28-day period in healthy adults and patients with type 2 diabetes mellitus. Volixibat was found to be well tolerated. In non-alcoholic steatohepatitis, increased faecal bile acid (BA) excretion and serum 7α-hydroxy-4-cholesten-3-one (C4) levels supported the mechanistic rationale for exploring apical sodium-dependent bile acid transporter inhibition.